Business
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition
LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for
About this update from Curis, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH) which will be held virtually from December 5-8, 2020. \n\n \n \n \n \n \n \n\n \n\"We are pleased with the progress to date for our first-in-class IRAK4 kinase inhibitor, CA-4948 and are on track to report data by year-end for both our Phase 1 study in patients with non-Hodgkin's lymphoma and our Phase 1 study in patients with acute myeloid leukemia and myelodysplastic syndromes,\" said James Dentzer, President and Chief Executive Officer of Curis. \"In addition to the data published in the abstracts this morning, we look forward to providing updated safety and efficacy data at ASH from both studies.\" \nDetails of the presentations are as follows:Oral Presentation:\nTitle: Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study Author: Grzegorz S. Nowakowski, MD, Mayo Clinic Session Name: 623. Mantle Cell and Indolent B-Cell Lymphoma - CAR-T and immunotherapy clinical studies Session Date & Time: Monday, December 7, 2020, 1:30 pm – 3:00 pm ET Presentation Time: 2:15 pm Poster Presentation\nTitle: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Author: Guillermo Garcia-Manero, MD, MD Anderson Cancer Center Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Session Date & Time: Monday, December 7, 2020, 10:00 a.m. – 6:30 p.m. ETPoster Presentation\nTitle: A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a novel IRAK4 inhibitor CA-4948 in combination with ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies Author: Grzegorz S. Nowakowski, MD, Mayo Clinic Session Name: 623. Mantle Cell, Follicular, and Other Indole...